Combination Treatment of tPA and Apyrase for Stroke
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we
have successfully engineered a human apyrase which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type apyrases. Importantly, the optimized apyrase conferred cerebroprotection against experimental stroke while preve
nting intracerebral hemorrhage. With the Phase II grant support, we will determine whether apyrase therapy is more effective while having lower bleeding risk than aspirin and a GPIIb/IIIa receptor antagonist, in combination with r-tPA for thrombolysis of s
troke occlusion. PUBLIC HEALTH RELEVANCE: We will utilize clinically relevant embolic stroke models in rats to validate whether human apyrase improves efficacy and reduce cerebral hemorrhage associated with thrombolytic treatment of ischemic stroke.
Small Business Information at Submission:
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 4041 Forest Park Avenue SAINT LOUIS, MO -
Number of Employees: